CLINICAL_TRIALS
trial_result
· 2017-02-01
Clinical Trial Update: Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS) [Phase 2]
Summary
A Phase 2 safety and efficacy trial of IPX159 for Restless Legs Syndrome has completed. The study was sponsored by Impax Laboratories, LLC.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Impax Laboratories, LLC | Conditions: Restless Legs Syndrome | Phase 2 | Status: COMPLETED